Critical Analysis of the Emerging Trispecific Landscape
Dawn of a new era or a setting sun on a tricky approach…
Three is a magic number – except when it isn’t.
Trispecific antibodies are one of the emerging stars on the multispecific stage, promising to hit not one, not two, but three targets with a single swing. It’s a tempting idea – who doesn’t love a good triple play?
With great ambition also comes great complexity, and not every design is ready for primetime.
At this year’s AACR, the trispecific party got a little louder.
From PD-1/CTLA-4/VEGF mashups to CD3-based T cell whisperers, the posters are brimming with innovation – and more than a few eyebrow-raisers.
So before we get swept up in the hype, let’s pause and ask a provocative question: is this a triple threat or a triple headache waiting to happen?
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
Not in San Diego – What we wanted to explore in this post was some nice examples of either creative thinking outside the box or where researchers have challenged existing dogma and revealed some intriguing or unexpected findings. These are all examples from talks or posters showcased yesterday during the second AACR virtual meeting…